[Source: Celltrion Inc.]
Celltrion Inc. has signed a partnership contract with U.S. TriLink BioTechnologies to develop a next-generation messenger RNA vaccine platform that can be applied to coronavirus variants, the South Korean pharmaceutical giant announced on Wednesday.
TriLink, a San Diego-based contract development and manufacturing organization (CDMO), has its own vector and third-generation capping technology (Clean Cap) essential for the development of mRNA vaccines, as well as the capability for clinical trial material supply and technology transfer, Celltrion said.
Under the agreement, TriLink will produce candidate substances for mRNA vaccines and DNA needed to make mRNA and supply the materials to Celltrion for Phase 1 and 2 clinical trials of mRNA vaccines using its unique capping technology along with antigen sequence verification. It will also provide Celltrion with template vector and mRNA processing technology for GMP-scale production.
Celltrion aims to develop a new Covid-19 vaccine effective against variants based on this technology. The company will also speed up the development of its own mRNA platform technology by using its patented technology.
“Through this collaboration, we will secure our own mRNA platform technology, which will also be applied to drug development in various fields," said a company official.
By Kim Si-gyun and Minu Kim
[ⓒ Pulse by Maeil Business Newspaper & mk.co.kr, All rights reserved]